从激活血液中高效分离CD34+造血干细胞

近年来,多能造血干细胞(HSC)治疗因其一系列的具有希望的疗效已成为一种流行的技术。广泛的可能性使这种前沿治疗方法成 为现代医学的转折点。该技术面临的其中一个公认的挑战是为移植快速获得足够数量的高纯度的所需细胞类型。目前,耗时的样 品制备步骤和在此过程中大量细胞损失仍然是一个重大的挑战。MARS®平台通过一种简单的方法从激活的血液中分离CD34+细胞,而不需要RBC裂解和密度梯度离心。

从全血中直接分离高纯度 CD138+浆细胞

骨髓浆细胞(BM)的细胞遗传学特异性特征是诊断和监测多发性骨髓瘤(MM)的一种常见的基因检测方法。多发性骨髓瘤患者的浆细 胞比例从1%到100%不等。尽管有些研究显示外周血中循环浆细胞(CPCs)比在骨髓中的风险低100倍以上,但由于其样本采集的侵入性 较低,它们的存在仍被认为是多发性骨髓瘤患者预后的一个重要标志。然而,耗时的样品制备步骤和在此过程中大量的细胞损失仍是一 个重大的挑战。MARS®平台通过一种简单的方法从外周血中分离CD138+浆细胞,而不需要RBC裂解和密度梯度离心。

High Purity Plasma CD138+ Cell Isolation straight from Whole Blood

Characterization of Plasma Cells in Bone Marrow (BM) for cytogenetic abnormalities is a common genetic test to diagnose and monitor multiple myeloma (MM). Plasma cells in MM patients vary in proportion from <1% up to 100%. Even though Circulating Plasma Cells (CPCs) burden in peripheral blood is reported to be >100-fold lower than in BM, their presence […]

High Efficiency Separation of CD34+ HSC from Mobilized Blood

In recent years multipotent haematopoietic stem cell (HSC) therapy has become a popular technique with a range of promising health benefits. A broad variety of possibilities makes this cutting-edge therapy a turning point in modern medicine. One of the recognized challenges is the ability to quickly obtain a sufficient number of desired cell types for transplantation, with […]

CD138+ Plasma Cell Enrichment from Whole Blood and Bone Marrow

CD138 expression is a hallmark of plasma cells and multiple myeloma cells, and it is considered a useful marker in plasma cells tumors diagnostics. Using our newly developed MARS® CS system (multi-physics automated reconfigurable separation) we demonstrate a cost-efficient, fast and robust workflow for isolation of CD138+ cells from whole blood and bone marrow samples within a short […]

A New Approach for High Recovery and Purity Isolation of Plasma Cells from Whole Blood

Characterization of Plasma Cells in Bone Marrow for different cytogenetic abnormalities is a common genetic test to diagnose and monitor cell malignant disease such as multiple myeloma (MM). Plasma cells in MM patients varied in proportion from <1% up to 100%. For the less invasive sample collection, circulating plasma cells (CPCs) in peripheral blood have emerged as an important […]

Enhanced Rare Cell Sorting Capability Enabled by MARS and WOLF 

MARS acoustic technology utilizes active-microfluidics acoustics for the separation of sample particles without labeling, based only on the difference in their physical parameters. The isolated cells are ready for negative MARS MAG selection, where cells bound to magnetic beads are captured in flow channels, without the need for dedicated columns. Combining the two technologies, MARS enables […]

High purity and recovery Positive Selection of CD34+ cells from Whole Blood

CD34+ cell isolation from whole blood is usually performed with RBC lysis or a density gradient separation method, typically using Ficoll – based protocols. This methodology is very time and labor-intensive and leads to high cell loss. Our No-Lyse-No-Wash (NLNW) protocol is fast and cost-effective. The MARS Bar system together with MARS MAG LINE of […]

Rare Cancer Cell Isolation From Whole Blood Using the MARS Cell Separation System

Circulating tumor cells (CTCs) are cancer cells shed from tumors and circulate in the bloodstream. These cells are considered to be a biomarker which potentially has high value in cancer diagnosis and cancer drug development. However, because of the extremely low frequency of CTC in peripheral blood, which is typically as low as less than […]